The company’s introductory offer ends on March 31
For Pfizer, the deal represents another attempt to get into an obesity treatment market
The U.K.’s FTSE 100 index closed the session marginally higher
Danish pharmaceutical giant Novo Nordisk was 1.3% lower
Scientific sessions addressed strategies to improve access to care
Mining stocks were the worst performers, slipping 1%
Novo Nordisk has already applied in the U.S. and EU to expand the pill’s approval
CagriSema is being investigated by Novo Nordisk as a weight-loss drug for adults
Novo Nordisk gained 3%. On Monday